Optogenetic Therapy Restores Partial Vision - Optics & Photonics News
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
A gene therapy makes surviving retinal ganglion cells light-sensitive, allowing blind patients to detect objects using stimulating goggles. [Image: IOB, Veronique Juvin, 2021]
An international team of researchers has shown that optogenetic therapy can improve the vision of people who have become blind through an inherited eye disease (N. Engl. J. Med., doi: 10.1056/NEJMoa2602215). Clinical tests showed that seven out of the 10 patients became more sensitive to light while some of the participants were also able to detect and reach for specific objects.
This article is an excerpt. To read the full content, visit the original source. Optics & Photonics News
Related articles
Interior Health restores services in Clinton - CFJC Today Kamloops
Optogenetic therapy shows promise for vision restoration - Physics World
Restoring visual function A gene therapy that makes surviving retinal ganglion cells light-sensitive allows blind patients to detect objects using stimulating goggles. (Courtesy: ©IOB, Veronique Juvin, 2021) Retinitis pigmentosa is an inherited degenerative condition that destroys photoreceptors in the retina and can eventually lead to irreversible blindness. In a clinical trial first, an international research team has demonstrated that optogenetic therapy is safe to use and shows potential for restoring visual function in patients with late stages of this disorder.
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!